Back to today’s briefing

Story perspectives

Hims & Hers Stock Dips Amid Layoffs, FDA Regulations

6/1/2025

50 11

Summary

Story summary

Hims & Hers Health (HIMS) experiences stock volatility, down 14% after layoffs linked to FDA regulations on Wegovy.
The company aims for long-term growth, partnering with Novo Nordisk to offer discounted Wegovy.
Despite a 125% year-to-date stock surge, high price-to-earnings ratios prompt investment caution.
HIMS demonstrates strong financial health with impressive revenue growth, though operating margins lag behind the S&P 500.

1 of 1

Story summary

Hims & Hers Health (HIMS) experiences stock volatility, down 14% after layoffs linked to FDA regulations on Wegovy.
The company aims for long-term growth, partnering with Novo Nordisk to offer discounted Wegovy.
Despite a 125% year-to-date stock surge, high price-to-earnings ratios prompt investment caution.
HIMS demonstrates strong financial health with impressive revenue growth, though operating margins lag behind the S&P 500.